BL

BioAge Labs, Inc.

BIOA·NASDAQ

$16.04

-3.0%
HealthcareBiotechnology

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.

At a Glance

Live Snapshot
Market Cap$603.90M
EPS-2.2400
P/E Ratio-7.16
Earnings Date08/05/2026

bioa

Interest Expense

Last Annual Value

697.00K

3-Year CAGR

42%

5-Year CAGR

24%

10-Year CAGR

11%

BL

BioAge Labs, Inc. Competitors Analysis of Interest Expense

BIOA · NASDAQ
CompanyInterest Expense
CAGR 3Y
CAGR 5Y
CAGR 10Y
697.00K
-55.3%N/AN/A 
0.00
N/AN/AN/A
2.00M
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
11.25M
19.5%20.9%N/A
0.00
N/AN/AN/A
9.16M
-19.5%113.2%68.1%
0.00
N/AN/AN/A
3.70M
29.6%-12.1%9.2%
16.40M
31.1%-1.1%N/A
BL

BioAge Labs, Inc. Fair Value Envelope

BIOA · NASDAQ

Our analysis suggests that BIOA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $16.04, this represents a potential HIDDEN relative to our calculated worth for BioAge Labs, Inc..

Intrinsic Value
Current Price: $16.04